丙戊酸镁缓释片联合帕罗西汀治疗老年脑卒中后抑郁的疗效

目的观察丙戊酸镁缓释片联合帕罗西汀治疗老年脑卒中后抑郁的疗效及安全性。方法将76例老年脑卒中后抑郁患者随机分为实验组(帕罗西汀联合丙戊酸镁缓释片治疗)和对照组(单用帕罗西汀治疗)。采用汉密尔顿抑郁量表(HAMD-17)评定疗效,用副反应量表(TESS)评定不良反应,中国神经功能缺损评分(CSS)量表评定神经功能改善程度。结果实验组显效率为73.68%,对照组为52.63%。实验组从第2周末起HAMD分、CSS分低于对照组,差异有统计学意义。2组间不良反应差异无统计学意义(P0.05)。结论丙戊酸镁缓释片联合帕罗西汀治疗脑卒中后抑郁较单用帕罗西汀起效更快,疗效更好,不良反应低,且能更好的促进神经功能的恢复。     

丙戊酸镁缓释剂合并帕罗西汀治疗难治性抑郁症对照研究

目的：观察丙戊酸镁合并帕罗西汀治疗难治性抑郁症组的疗效及安全性。方法：将50例难治性抑郁症患者随机分为合用组（丙戊酸镁缓释剂合并帕罗西汀）25例和单用组（帕罗西汀组）25例。疗程6周。分别评定汉密尔顿抑郁量表（HAMD）和治疗中出现的症状量表（TESS）。结果：合用组HAMD量表分于治疗3周显著下降,单用组HAMD分于治疗4周显著下降,合用组有效率显著高于单用组35％（P〈0．05）。结论：丙戊酸镁缓释剂合并帕罗西汀治疗难治性抑郁疗效确切。     

丙戊酸镁治疗癫痫

丙戊酸镁治疗癫痫张敬军，陈青，孙思琴丙戊酸镁是继丙戊酸钠、癫痫安之后合成的另一丙戊酸类药，国外７０年代开始用于临床，国内应用尚少，本文单用丙戊酸镁治疗各型癫痫８３例，并监测血浓度，现就临床疗效、血浓度测定、脑电图变化及其不良反应加以分析及讨论。１资料...     

丙戊酸镁缓释片治疗精神分裂症的辅助作用

目的:探讨阿立哌唑合用丙戊酸镁缓释片治疗难治性精神分裂症患者的疗效及安全性。方法:60例难治性精神分裂症患者随机分为两组,分别给予阿立哌唑合用丙戊酸镁缓释片与阿立哌唑单用治疗,疗程8周。用阳性与阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:阿立哌唑合用丙戊酸镁缓释片治疗难治性精神分裂症的疗效优于单用阿立哌唑(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论:阿立哌唑合用丙戊酸镁缓释片治疗难治性精神分裂症疗效好,安全性好。     

丙戊酸镁治疗躁狂症36例

作者介绍了丙戊酸镁治疗36例躁狂症的疗效及副反应。显效率为80.6%,有效率为94.4%,发现该药治疗躁狂症显效率高,且疗效与病程有关,与日治疗剂量的大小无关。BRMS量表观察显示精神症状消退快,TESS评估发现该药副反应少,文章还就该药治疗蹂狂症的机理进行了初步探讨。     

米氮平与帕罗西汀治疗广泛性焦虑的对照研究

为探讨米氮平治疗广泛性焦虑患者的疗效,我们以帕罗西汀为对照,研究2药对广泛性焦虑的疗效,报告如下. 1 对象和方法 选自2005年7月至2006年7月我院住院和门诊患者,符合中国精神障碍分类与诊断标准第3版广泛性焦虑障碍的诊断标准;既往未用过抗抑郁剂治疗;排除严重的器质性疾病、物质依赖及哺乳期妇女.     

丙戊酸镁治疗快速循环型情感性障碍

快速循环型情感障碍是临床上治疗和预防十分棘手的疾病,各类抗躁狂剂包括碳酸锂、氯硝安定等亦仅对20%的患者有效,作者用丙戊酸镁治疗了3例历经各类抗躁狂剂无效取得意外良效,希望引起同道兴趣而广泛深入应用与观察。     

度洛西汀与帕罗西汀治疗广泛性焦虑的对照分析

目的：评价度洛西汀治疗广泛性焦虑的临床疗效及安全性。方法对84例广泛性焦虑患者随机分为度洛西汀组和帕罗西汀组各42例，治疗8周，采用汉密尔顿焦虑量表（HAMA）和临床疗效总评量表、病情严重程度（CGI-SI）评定临床疗效，副反应量表（T ESS ）评定药物不良反应。结果经8周治疗，度洛西汀组和帕罗西汀组有效率分别为85.71％和83.33％，显效率分别为66.67％和64.29％，2组比较差异无统计学意义（ P＞0.05），2组不良反应发生率比较差异无统计学意义（ P＞0.05）。结论度洛西汀治疗广泛性焦虑安全有效，不良反应轻微，值得临床推广。     

米氮平与帕罗西汀治疗广泛性焦虑障碍的对照研究

目的评价米氮平治疗广泛性焦虑障碍的临床疗效及安全性。方法将76例符合中国精神障碍分类与诊断标准第三版（CCMD-3）诊断标准的广泛性焦虑障碍患者（GAD）随机分为米氮平组和帕罗西汀组治疗8周,采用汉密顿焦虑量表（HAMA）、临床疗效总评量表（CGI）、副反应量表（TESS）在治疗前和第2、4、6、8周评定临床疗效及不良反应。结果经8周治疗后,显效率分别为81.6%和84.2%,两组比较,差异无显著性（P〉0.05）。结论米氮平和帕罗西汀对广泛性焦虑障碍的治疗效果相当,且副反应轻,均可作为临床治疗GAD的一种选择。     

丙戊酸镁对脑梗死所致精神障碍的辅助治疗

目的:探讨丙戊酸镁对腔隙性脑梗死所致精神障碍的辅助治疗作用.方法:对脑梗死所致精神障碍患者67例,随机分为利培酮合并丙戊酸镁(合用组)和单用利培酮(单用组),疗程8周.治疗前及治疗第2、4、6、8周分别用简明精神病评定量表(BPRS)评定疗效,用副反应量表(TESS)评定不良反应.结果:治疗结束时两组均有较好疗效,而以合用组起效较快、疗效较高.两组不良反应相仿.结论:利培酮合并丙戊酸镁治疗腔隙性脑梗死所致精神障碍有效.     

Paroxetine efficacy in the treatment of generalized anxiety disorder

Recently, there has been a renewed interest in alternatives to the benzodiazepines for the treatment of generalized anxiety disorder (GAD). The aim of the present study was to compare the efficacy of paroxetine vs. imipramine and 2′-chlordesmethyldiazepam in 81 patients with a DSM-IV diagnosis of GAD. Approximately two-thirds of the patients who completed the study improved greatly or moderately on all three active drugs. During the first 2 weeks of treatment, 2′-chlordesmethyldiazepam treatment resulted in the greatest improvement in anxiety ratings. Both paroxetine and imipramine treatment resulted in more improvement than 2′-chlordesmethyldiazepam by the fourth week of treatment. Paroxetine and imipramine affect predominantly psychic symptoms, whereas 2′-chlordesmethyldiazepam affects predominantly somatic symptoms. Our results suggest that paroxetine is effective for the treatment of GAD.     

文拉法辛治疗广泛性焦虑对照观察

目的:比较文拉法辛与帕罗西汀治疗广泛性焦虑的临床疗效及不良反应。方法:将60例广泛性焦虑患者随机分为文拉法辛组(30例)及帕罗西汀组(30例),疗程8周。用焦虑自评量表(SAS)、汉密尔顿焦虑量表(HAMA)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:治疗第2周末文拉法辛组SAS、HAMA总分与治疗前相比下降较帕罗西汀组更明显(P均<0.05)。治疗第2、4周末,文拉法辛组有效率分别为20%和56%,帕罗西汀组分别为3%和26%,组间差异均有显著性(P均<0.05);治疗第6周末,文拉法辛组治愈率为50%,帕罗西汀组为23%,组间差异有显著性(P<0.05);而两组间有效率差异无显著性(P>0.05)。结论:文拉法辛治疗广泛性焦虑安全有效,不良反应少。     

西酞普兰与帕罗西汀治疗广泛性焦虑对照研究

目的:探讨西酞普兰治疗广泛性焦虑的疗效及安全性。方法:将80例广泛性焦虑患者随机分为西酞普兰组及帕罗西汀组各40例,2药治疗剂量均为20～40mg/d。疗程4周。用Hamilton焦虑量表(HAMA)、焦虑自评量表(SAS)及治疗中出现的症状量表(TESS)评定疗效及不良反应。结果:西酞普兰组有效率为85.0%,帕罗西汀组为87.5%,两组疗效相当(P>0.05)。西酞普兰组不良反应较帕罗西汀组少且轻微,患者依从性好。结论:西酞普兰是一种安全、有效的抗焦虑药。     

Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder

This trial was to evaluate the efficacy and tolerability of venlafaxine extended release (XR) and paroxetine for treatment of patients with generalized anxiety disorder (GAD). Sixty patients who met DSM-IV criteria for GAD were randomly assigned to either venlafaxine XR or paroxetine for 8 weeks. Efficacy was assessed with the Hamilton Rating Scale for Anxiety (HAM-A) and Clinical Global Impression-Severity of Illness (CGI-S) scale at the baseline, week 1, week 4, and week 8. The side-effects were collected with reported adverse events and laboratory tests throughout the study period. Repeated measures analysis of variance (ANOVA) on the HAM-A and CGI-S scores showed a significant decrease over time in both treatment groups without significant group difference or time x group interaction effect. There were no serious adverse events in both groups. This open trial demonstrated that either venlafaxine XR or paroxetine would be effective and tolerable for the treatment of patients with GAD. Double blind, placebo-controlled head-to-head comparison studies are needed to draw a definite conclusion.     

度洛西汀与文拉法辛治疗广泛性焦虑对照研究

目的：比较度洛西汀与文拉法辛治疗广泛性焦虑的疗效及不良反应。方法：对90例广泛性焦虑症住院患者,随机分为两组,度洛西汀组和文拉法辛组各45例,治疗8周,采用汉密尔顿焦虑量表（HAMA）和临床疗效总评量表病情严重程度（CGI-SI）评定临床疗效,用治疗中出现的症状量表（TESS）评定药物不良反应。结果：经过8周治疗,度洛西汀组和文拉法辛组有效率分别为84．44％和82．22％,两组疗效差异无统计学意义（P〉0．05）,两组不良反应发生率差异无统计学意义（P〉0．05）。结论：度洛西汀和文拉法辛对广泛性焦虑症的疗效相当,不良反应较小,值得临床推广。     

Duloxetine in the treatment of generalized anxiety disorder

Duloxetine, a medication with effects on both serotonin and noradrenaline transporter molecules, has recently been approved for the treatment of generalized anxiety disorder. The evidence for its efficacy lies in a limited number of double blind, placebo controlled comparisons. Statistically significant improvements in the Hamilton Anxiety Rating Scale from baseline were demonstrated in all studies at doses of 60 to 120 mg per day. The significance of such changes in terms of clinical improvements compared to placebo is less certain, particularly when the effect size of the change is calculated. In comparative trials with venlafaxine, duloxetine was as effective in providing relief of anxiety symptoms. In addition to improvements in clinical symptoms duloxetine has also been associated with restitution of role function as measured by disability scales. Duloxetine use is associated with nausea, dizziness, dry mouth, constipation, insomnia, somnolence, hyperhidrosis, decreased libido and vomiting. These treatment emergent side effects were generally of mild to moderate severity and were tolerated over time. Using a tapered withdrawal schedule over two weeks in the clinical trials, duloxetine was associated with only a mild withdrawal syndrome in up to about 30% of patients compared to about 17% in placebo treated patients. Duloxetine in doses of up to 200 mg twice daily did not prolong the QTc interval in healthy volunteers. Like other agents with dual neurotransmitter actions duloxetine reduces the symptoms of generalized anxiety disorder in short term treatments. Further evidence for its efficacy and safety in long term treatment is required.     

米氮平治疗广泛性焦虑对照研究

目的:比较米氮平与阿普唑仑治疗广泛性焦虑的临床疗效及不良反应。方法:采用随机分组的方法,对66例广泛性焦虑随机平分为米氮平组(33例)和阿普唑仑组(33例)。疗程6周。用焦虑自评量表(SAS)、Hamilton焦虑量表(HAMA)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:米氮平与阿普唑仑疗效相当,不良反应米氮平组较阿普唑仑组少而轻。结论:米氮平治疗广泛性焦虑安全、有效,且不良反应轻微。     

百麦安神饮对广泛性焦虑障碍的辅助治疗作用

目的：观察文拉法辛缓释片与百麦安神饮联合应用对广泛性焦虑障碍的疗效和安全性。方法：采用对照研究,治疗组患者给予百麦安神饮和文拉法辛缓释片口服,对照组患者给予文拉法辛缓释片口服。以汉密尔顿焦虑量表（HAMA）和治疗中出现的症状量表（TESS）在治疗前及治疗1、2、4、6周分别评定两组患者的广泛性焦虑症状改善情况及药物不良反应。结果：两组治疗后均有显著疗效,两组疗效相仿（P〉0.05）。治疗组不良反应明显小于对照组（P〈0.01）。结论：文拉法辛缓释片结合百麦安神饮治疗广泛性焦虑障碍,疗效可靠,不良反应小,服药依从性好。     

丙戊酸镁与碳酸锂治疗躁狂发作对照研究

目的:比较丙戊酸镁与碳酸锂治疗躁狂发作的疗效和不良反应。方法:对84例躁狂发作患者随机平分为丙戊酸镁组和碳酸锂组,在治疗前及治疗2、4、6周末分别用Bech-Rafaelsen躁狂量表(BRMS)、临床疗效总评量表(CGI)及副反应量表(TESS)评定疗效和不良反应。结果:丙戊酸镁组治疗2周末BRMS总分及各因子分比治疗前明显降低,且显著低于碳酸锂组。丙戊酸镁的不良反应与碳酸锂相似,但持续时间较短,患者耐受性好。结论:丙戊酸镁治疗躁狂发作疗效好,起效快,不良反应小。